antitrust probe

Trip.com facing class action lawsuit following 17% stock plunge on antitrust investigation by China's market regulator for alleged monopolistic practices.

Trip.com faces securities fraud class action after China's antitrust regulator launches monopoly investigation. Stock fell 19.4% following January announcement.

Pomerantz Law Firm sues Trip.com for securities fraud following China antitrust probe; stock fell 17%. Investors have until May 11, 2026, to claim Lead Plaintiff status.

Portnoy Law Firm launches class action against $TCOM for allegedly concealing antitrust risks. Stock plunged 19% after China probe disclosure.

Trip.com faces securities fraud lawsuit after China's antitrust probe alleges monopolistic practices; stock fell 19.4%. Investors may file lead plaintiff applications until May 11, 2026.

Trip.com faces securities fraud lawsuit after Chinese antitrust regulators probe alleged monopolistic practices. Stock fell 19.4% in January 2026.

Trip.com faces securities fraud lawsuit after China's antitrust regulator probed alleged monopolistic practices. Stock fell 19.4% in January 2026.

Robbins LLP filed class action against $TCOM for allegedly concealing antitrust risks. Stock dropped 19.4% after January 2026 antitrust probe disclosure.

Trip.com faces securities fraud lawsuit following SAMR antitrust investigation into monopolistic practices. Stock declined 19.4% post-disclosure; investors have until May 2026 to join action.

Trip.com faces securities fraud class action after China's antitrust regulator probes alleged monopolistic practices. Stock fell 19.4% in January 2026.

Trip.com ($TCOM) tumbled 17% after China's antitrust regulator launched investigation into alleged monopolistic practices. Lead plaintiff deadline set for May 11, 2026.

Law firm files class actions against uniQure, Gartner, and Trip.com for alleged failure to disclose material information. Stock declines range from 19% to 49%.

Trip.com faces securities fraud lawsuit after Chinese antitrust probe alleges monopolistic practices; stock fell 19.4%. Investors have until May 11, 2026 to file claims.

Driven Brands Holdings faces securities fraud class action over undisclosed financial statement errors spanning 2023-2025, triggering a 39% stock decline.

Class action lawsuit filed against Corcept Therapeutics alleging securities fraud tied to FDA rejection of relacorilant, triggering 50% stock plunge.

Trip.com faces securities lawsuit after 19% stock plunge following China antitrust investigation disclosure. Lead plaintiff deadline set for May 11, 2026.

Trip.com investors with $100K+ losses must file lead plaintiff claims by May 11, 2026 in securities lawsuit stemming from China's antitrust investigation.

Trip.com stock plummeted 17% after China's antitrust regulator launched investigation into alleged monopolistic practices, sparking class action lawsuit.

Trip.com ($TCOM) plummeted 17% after China's market regulator launched antitrust investigation. Class action lawsuit targets investors with losses exceeding $100,000.

Trip.com faces securities fraud lawsuit after China's antitrust probe; stock plunged 19.4% with investors losing $12.90 per share initially.